Pilot Progress: WellDoc Announces Providence Health & Services’ Implementation of BlueStar Digital Therapeutic

Ahead of the weekend, WellDoc announced a pilot program in the Providence Health & Services Oregon/SW Washington Region to examine the use of WellDoc’s BlueStar, an FDA-cleared, proven digital therapeutic for individuals with type 2 diabetes.

According to a provided release, the Providence Health & Services pilot program will include individuals living with type 2 diabetes and will evaluate the impact of a digital therapeutic—when used in conjunction with the support of a dedicated Diabetes Educator—on user engagement, retention, satisfaction and clinical outcomes.

“We’re pleased to announce this pilot program with Providence Health & Services,” said WellDoc President and CEO Kevin McRaith. “We expect great outcomes from this initial engagement and look forward to expanding our partnership to scale to meet the needs of all Providence patients living with type 2 diabetes.”

BlueStar provides real-time and timely individualized coaching and support, as well as diabetes educational tools that are actionable and personal for individuals living with type 2 diabetes.

Clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar.

BlueStar harnesses evidence-based diabetes management, behavior management, and user experience to engage and provide individualized guidance when needed to people with type 2 diabetes.

To learn more about the pilot and the program, click here.

This post was written by:

- who has written 626 posts on mHealthWatch.

Contact the author